




Title	Simulation studies to assess the long-term effects of Japan's change from trivalent to quadrivalent influenza vaccination
Author(s)	Tsuzuki, Shinya; Schwehm, Markus; Eichner, Martin
Citation	Vaccine, 36(5), 624-630 <a href="https://doi.org/10.1016/j.vaccine.2017.12.058">https://doi.org/10.1016/j.vaccine.2017.12.058</a>
Issue Date	2018-01-29
Doc URL	<a href="http://hdl.handle.net/2115/71750">http://hdl.handle.net/2115/71750</a>
Rights(URL)	<a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>
Type	article
Note	Corrigendum: Vaccine. 36(45), 2018, p.6893, DOI:10.1016/j.vaccine.2018.09.046
Additional Information	There are other files related to this item in HUSCAP. Check the above URL.
File Information	1-s2.0-S0264410X1831315X-main.pdf (Corrigendum)



[Instructions for use](#)

Contents lists available at [ScienceDirect](#)

# Vaccine

journal homepage: [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)

## Corrigendum

### Corrigendum to “Simulation studies to assess the long-term effects of Japan’s change from trivalent to quadrivalent influenza vaccination” [Vaccine 36 (2018) 624–630]

Shinya Tsuzuki <sup>a,\*</sup>, Markus Schwehm <sup>b</sup>, Martin Eichner <sup>c,d</sup><sup>a</sup> Department of Hygiene, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan<sup>b</sup> ExploSYS GmbH, Leinfelden, Germany<sup>c</sup> Department for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany<sup>d</sup> Epimos GmbH, Dußlingen, Germany

The authors regret that they reported two incorrect values in their paper. In the Abstract and in section 3.2, they claimed that in Japan’s population of 125.35 million, annually 91.51 YOLs are gained by QIV and 10.75 million USD are saved, but these values should be 915.06 YOLs and 107.52 million USD, respectively.

These extrapolated values for the total Japanese population were only used as illustration; they neither affected other results nor the discussion or conclusion. The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.vaccine.2017.12.058>

\* Corresponding author at: Department of Hygiene, Graduate School of Medicine, Hokkaido University, Kita 15-jo Nishi 7 Chome, Kita-ku, Sapporo 060-8638, Japan.

E-mail address: [stsuzuki@med.hokudai.ac.jp](mailto:stsuzuki@med.hokudai.ac.jp) (S. Tsuzuki).

<https://doi.org/10.1016/j.vaccine.2018.09.046>

0264-410X/© 2018 The Author(s). Published by Elsevier Ltd.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).